Imaging characteristics and diagnostic value of magnetic resonance imaging for hepatocellular carcinoma in patients with alpha-fetoprotein < 20ng/mL

  • Nguyễn Văn Tấu Bệnh viện Quân y 109
  • Nguyễn Xuân Khái Bệnh viện Quân y 103
  • Trần Công Hoan Bệnh viện E
  • Nguyễn Minh Châu Bệnh viện Phụ sản Trung ương

Main Article Content

Keywords

Hepatocellular carcinoma; magnetic resonance imaging; low AFP; diagnostic value; DWI.

Abstract

Objective: To describe imaging characteristics and evaluate the diagnostic value of magnetic resonance imaging (MRI) for hepatocellular carcinoma (HCC) in patients with alpha-fetoprotein (AFP) < 20 ng/mL. Subjects and method: A prospective cross-sectional study with histopathological correlation was conducted in 122 patients with AFP < 20 ng/mL who underwent liver MRI at K Hospital, Tan Trieu Campus, from June 2025 to December 2025. MRI diagnosis was based on LI-RADS 2018 in high-risk patients and a multiparametric assessment in patients not belonging to the high-risk group. Result: There were 57 HCC and 65 non-HCC lesions. HCC was mainly mass/nodular type (98.25%), solitary (66.67%), with a mean size of 43.56 ± 19.04 mm. Common MRI findings included non-rim APHE (94.74%), T2 hyperintensity (96.49%), T1 hypointensity (92.98%), DWI hyperintensity (96.49%), true diffusion restriction (70.18%), delayed washout (68.42%) and enhancing capsule (47.37%). MRI correctly identified 47 HCC cases, missed 10 HCC cases, correctly excluded HCC in 56 cases and yielded 9 false-positive cases. Sensitivity, specificity, PPV, NPV, accuracy and ROC-AUC were 82.46%, 86.15%, 83.93%, 84.85%, 84.43% and 0.843 (95%CI: 0.771-0.915), respectively. Conclusion: In patients with AFP < 20 ng/mL, HCC on MRI commonly shows non-rim APHE, T2/DWI hyperintensity, T1 hypointensity, diffusion restriction and more evident delayed washout, MRI showed high discriminatory performance for differentiating HCC from non-HCC liver lesions in this single-center cohort.

Article Details

References

1. International Agency for Research on Cancer. Global Cancer Observatory: Liver Cancer Fact Sheet. Lyon: IARC; 2022.
2. International Agency for Research on Cancer. GLOBOCAN 2022: Vietnam fact sheet. Lyon: IARC; 2022.
3. Forner A, Reig M, Bruix J (2018) Hepatocellular carcinoma. Lancet 391(10127): 1301-1314. doi:10.1016/S0140-6736(18)30010-2.
4. Yeo YH, Lee YT, Tseng HR, Zhu Y, You S, Agopian VG (2024) Alpha-fetoprotein: Past, present, and future. Hepatol Commun 8(5): 0422.
5. Wang T, Zhang KH (2020) New blood biomarkers for the diagnosis of AFP-negative hepatocellular carcinoma. Front Oncol 10: 1316. doi:10.3389/fonc.2020.01316.
6. Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA (2023) AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 78(6):1922-1965. doi:10.1097/HEP.0000000000000466.
7. Chernyak V, Fowler KJ, Kamaya A, Kielar AZ, Elsayes KM, Bashir MR et al (2018) Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology 289(3): 816-830. doi:10.1148/radiol.2018181494.
8. Roberts LR, Sirlin CB, Zaiem F, Almasri J, Prokop LJ, Heimbach JK, et al (2018) Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. Hepatology 67(1): 401-421. doi:10.1002/hep.29487.
9. Kim YY, Aljoqiman KS, Choi JY, Kim MJ Gadoxetic acid-enhanced magnetic resonance imaging: hepatocellular carcinoma and mimickers. Clin Mol Hepatol 25(3): 223-233. doi:10.3350/cmh.2019.0067.
10. Hwang J, Kim SH, Lee MW, Lee JY (2012) Small (≤2 cm) hepatocellular carcinoma in patients with chronic liver disease: comparison of gadoxetic acid-enhanced 3.0T MRI and multiphasic 64-multirow detector CT. Br J Radiol 85(1015): 314-322. doi:10.1259/bjr/74352862.
11. Nadarević T, Colli A, Giljaca V, Miletić D (2022) Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 5:CD014798. doi:10.1002/14651858.CD014798.pub2.
12. Tan CH, Low SC, Thng CH (2022) Gadoxetate-enhanced MRI as a diagnostic tool in the management of hepatocellular carcinoma: current evidence and recommendations. Korean J Radiol 23(3): 316-331. doi:10.3348/kjr.2021.0865.
13. Võ Tấn Đức, Nguyễn Quang Thái Dương, Lê Duy Mai Huyên và cộng sự (2024) Giá trị của cộng hưởng từ với chất tương phản đặc hiệu gan mật trong chẩn đoán ung thư biểu mô tế bào gan. Điện quang và Y học hạt nhân Việt Nam 54: 13-17.
14. Nguyễn Văn Sơn, Nguyễn Minh Châu, Lê Thị Nhung và cộng sự (2025) Đặc điểm hình ảnh cộng hưởng từ ung thư biểu mô tế bào gan tại Bệnh viện E. VNU J Sci Med Pharm Sci 41(2): 108-115.
15. European Association for the Study of the Liver (2025) EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J Hepatol 82(2):315-374.